CClinicalTrials.gg
CompletedNCT03409146Updated Feb 9, 2021

Accuracy and Reliability of Novii: Fetal Heart Rate (FHR), Maternal Heart Rate (MHR) and Uterine Contraction (UA) Compared With Doppler, Scalp Fetal Scalp Electrode (FSE), Tocodynamometer (TOCO) and Intra Uterine Pressure Catheter (IUPC)

An observational study in Term Labour, sponsored by GE Healthcare. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-09.

Sponsored by GE Healthcare · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Study summary

Accuracy and Reliability of the Novii device (fetal heart rate, maternal heart rate and uterine activity) compared with Food and Drug Administration (FDA) approved techniques

Read the detailed description

The study is being done to test the performance of a Novii Wireless Patch System for following the baby's and mother's heart rates and uterine contractions during labor. We want to find out if the new monitor works as well as other types of monitors that are usually used: Doppler Fetal Heart Rate (FHR), Scalp FHR, Tocodynamometer (TOCO) and Intra Uterine Pressure Catheter (IUPC).

80 patients will be monitored during the study.

02

Conditions studied

  • Term Labour
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant Women at Term

Inclusion criteria

A woman will be considered for inclusion in the study if she fulfills all of the following criteria:

  • She has a term or near term (≥36 completed weeks) singleton gestation in a cephalic presentation and has been admitted to the Labor and Delivery Unit .
  • She is in the latent phase of spontaneous labor, or has been admitted for induction of labor.
  • She has given her informed consent to participate as a subject.
  • She has none of the exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Known major fetal malformation or chromosome abnormality.
  • Multiple gestation
  • A condition for which cesarean will likely be carried out shortly.
  • Subject plans not to have electronic fetal monitoring.
  • Involvement in another clinical trial currently or previously in this pregnancy that, in the investigator's opinion, would affect the conduct of this study.
  • Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, history of sensitivity to adhesives).
  • Parturient is under age 18.
  • Medical or obstetric problem that in investigator's opinion would make the patient incapable of taking part in the study.
  • Inability to understand the consent information due to medical illness or diminished intellectual capacity, or insurmountable language barrier.
  • Potential for coercion, e.g. Medical Center employees, prisoners.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Term Patients

    Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton \>37 week pregnancy. Subjects will be recruited for the study in the following groups : At least 10 patients with Body Mass Index (BMI) \< 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2

    Device: Monica Novii Wireless Patch System

Interventions

  • DeviceMonica Novii Wireless Patch System

    The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.

05

What researchers measure

Primary outcomes

  1. Fetal Heart Rate (FHR) Positive Percentage Agreement (PPA)

    PPA(%)=(a/(a+C))x100, where "a" represents the number of 2 second epochs when the Novii FHR is within +/-10% of the predicate device FHR for each 2 second epoch, and "c" are the number of 2 second epochs when the Novii FHR is not within +/- 10% of the predicate device FHR or is absent.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Mean Percentage FHR Equivalence

    The 2 second output FHR data when both the predicate and Novii devices are reporting a value will be considered. In this case for each 2 second epoch the FHR value from the Novii device is divided by the predicate device FHR value to create a "FHR ratio".

    Time frame: through study completion, an average of 1 year

  2. Uterine Activity (UA) Sensitivity (from Individual Contractions)

    The Sensitivity of the Novii System against the predicate device is determined from the "individual contraction "detection as follows: Sensitivity(%)=(x/(x+z))x100 Where: "x" is the total number of "individual contractions" detected by both the devices "z" is the total number of "individual contractions" detected by the predicate device only

    Time frame: through study completion, an average of 1 year

  3. Uterine activity Positive Percentage Agreement (from Interpretable Data)

    The positive percentage agreement (PPA) is determined from the interpretable and uninterpretable data as follows: PPA(%)=(a/(a+c))x100 Where: "a" is the number of minutes when both devices UA are "interpretable" at the same time "c" is the number of minutes when the predicate device UA is "interpretable" but the Novii system UA is "un-interpretable".

    Time frame: through study completion, an average of 1 year

  4. Maternal Heart Rate (MHR) Positive Percentage Agreement (PPA)

    PPA(%)=(a/(a+C))x100, where "a" represents the number of 2 second epochs when the Novii MHR is within +/-10% of the predicate device MHR for each 2 second epoch, and "c" are the number of 2 second epochs when the Novii MHR is not within +/- 10% of the predicate device MHR or is absent.

    Time frame: through study completion, an average of 1 year

  5. Mean Percentage MHR Equivalence

    The 2 second output MHR data when both the predicate and Novii devices are reporting a value will be considered. In this case for each 2 second epoch the MHR value from the Novii device is divided by the predicate device MHR value to create a "MHR ratio".

    Time frame: through study completion, an average of 1 year

06

Study locations

1 site
  • University of Arizona Medical Center
    Tucson, Arizona 85724, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03409146
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
May 28, 2014
Primary completion
Feb 13, 2017
Completion
Feb 13, 2017
Last update
Feb 9, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion